109 related articles for article (PubMed ID: 4017965)
1. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
2. Biological activities and receptor interactions of des-Leu16 salmon and des-Phe16 human calcitonin.
Findlay DM; Michelangeli VP; Orlowski RC; Martin TJ
Endocrinology; 1983 Apr; 112(4):1288-91. PubMed ID: 6299689
[TBL] [Abstract][Full Text] [Related]
3. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
4. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions.
Stroop SD; Nakamuta H; Kuestner RE; Moore EE; Epand RM
Endocrinology; 1996 Nov; 137(11):4752-6. PubMed ID: 8895343
[TBL] [Abstract][Full Text] [Related]
5. Biologically active, derivatizable salmon calcitonin analog: design, synthesis, and applications.
D'Santos CS; Nicholson GC; Moseley JM; Evans T; Martin TJ; Kemp BE
Endocrinology; 1988 Sep; 123(3):1483-8. PubMed ID: 2841096
[TBL] [Abstract][Full Text] [Related]
6. Renal receptors for calcitonin: coordinate occurrence with calcitonin-activated adenylate cyclase.
Marx SJ; Aurbach GD
Endocrinology; 1975 Aug; 97(2):448-53. PubMed ID: 169126
[TBL] [Abstract][Full Text] [Related]
7. A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats.
Yates AJ; Gutierrez GE; Garrett IR; Mencel JJ; Nuss GW; Schreiber AB; Mundy GR
Endocrinology; 1990 Jun; 126(6):2845-9. PubMed ID: 2351097
[TBL] [Abstract][Full Text] [Related]
8. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
Epand RM; Epand RF; Stafford AR; Orlowski RC
J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
[TBL] [Abstract][Full Text] [Related]
9. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
Orlowski RC; Epand RM; Stafford AR
Eur J Biochem; 1987 Jan; 162(2):399-402. PubMed ID: 3803393
[TBL] [Abstract][Full Text] [Related]
10. des-Ser2 salmon calcitonin: a biologically potent synthetic analog.
Schwartz KE; Orlowski RC; Marcus R
Endocrinology; 1981 Mar; 108(3):831-5. PubMed ID: 6257497
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase-C-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN cells.
Findlay DM; Michelangeli VP; Robinson PJ
Endocrinology; 1989 Nov; 125(5):2656-63. PubMed ID: 2551660
[TBL] [Abstract][Full Text] [Related]
12. The biological potency of a series of analogues of human calcitonin correlates with their interactions with phospholipids.
Epand RF; Orlowski RC; Epand RM
Biopolymers; 2004; 76(3):258-65. PubMed ID: 15148685
[TBL] [Abstract][Full Text] [Related]
13. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
14. Dual effects of calcitonin and calcitonin gene-related peptide on intracellular cyclic 3',5'-monophosphate in a human breast cancer cell line.
Barsony J; Marx SJ
Endocrinology; 1988 Apr; 122(4):1218-23. PubMed ID: 2831023
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
[TBL] [Abstract][Full Text] [Related]
16. Conformational flexibility and biological activity of salmon calcitonin.
Epand RM; Epand RF; Orlowski RC; Seyler JK; Colescott RL
Biochemistry; 1986 Apr; 25(8):1964-8. PubMed ID: 3707923
[TBL] [Abstract][Full Text] [Related]
17. Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes.
Twery MJ; Seitz PK; Nickols GA; Cooper CW; Gallagher JP; Orlowski RC
Eur J Pharmacol; 1988 Oct; 155(3):285-92. PubMed ID: 3266153
[TBL] [Abstract][Full Text] [Related]
18. Photoaffinity labeling of rat calcitonin gene-related peptide receptors and adenylate cyclase activation: identification of receptor subtypes.
Stangl D; Muff R; Schmolck C; Fischer JA
Endocrinology; 1993 Feb; 132(2):744-50. PubMed ID: 8381072
[TBL] [Abstract][Full Text] [Related]
19. Control of cyclic adenosine 3',5'-monophosphate production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase.
Nicholson GC; Moseley JM; Yates AJ; Martin TJ
Endocrinology; 1987 May; 120(5):1902-8. PubMed ID: 3032571
[TBL] [Abstract][Full Text] [Related]
20. A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats.
Kohno T; Nakamuta H; Ichikawa M; Watabe K; Koida M
J Clin Lab Anal; 1996; 10(2):91-7. PubMed ID: 8852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
